Pediatric high-grade glioma (HGG) is a devastating disease with a less than 20% survival rate 2 years after diagnosis 1 . We analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs), by whole-genome, whole-exome and/or transcriptome sequencing. We identified recurrent somatic mutations in ACVR1 exclusively in DIPGs (32%), in addition to previously reported frequent somatic mutations in histone H3 genes, TP53 and ATRX, in both DIPGs and NBS-HGGs 2-5 . Structural variants generating fusion genes were found in 47% of DIPGs and NBS-HGGs, with recurrent fusions involving the neurotrophin receptor genes NTRK1, NTRK2 and NTRK3 in 40% of NBS-HGGs in infants. Mutations targeting receptor tyrosine kinase-RAS-PI3K signaling, histone modification or chromatin remodeling, and cell cycle regulation were found in 68%, 73% and 59% of pediatric HGGs, respectively, including in DIPGs and NBS-HGGs. This comprehensive analysis provides insights into the unique and shared pathways driving pediatric HGG within and outside the brainstem.
Pediatric high-grade glioma (HGG) is a devastating disease with a less than 20% survival rate 2 years after diagnosis 1 . We analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs), by whole-genome, whole-exome and/or transcriptome sequencing. We identified recurrent somatic mutations in ACVR1 exclusively in DIPGs (32%), in addition to previously reported frequent somatic mutations in histone H3 genes, TP53 and ATRX, in both DIPGs and NBS-HGGs 2-5 . Structural variants generating fusion genes were found in 47% of DIPGs and NBS-HGGs, with recurrent fusions involving the neurotrophin receptor genes NTRK1, NTRK2 and NTRK3 in 40% of NBS-HGGs in infants. Mutations targeting receptor tyrosine kinase-RAS-PI3K signaling, histone modification or chromatin remodeling, and cell cycle regulation were found in 68%, 73% and 59% of pediatric HGGs, respectively, including in DIPGs and NBS-HGGs. This comprehensive analysis provides insights into the unique and shared pathways driving pediatric HGG within and outside the brainstem.
Although childhood and adult HGGs share related histopathological characteristics, adult HGGs arise predominantly in the cerebral cortex, whereas childhood HGGs more frequently involve a broader spectrum of locations. There are also substantial differences in the molecular features of pediatric and adult HGGs 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Histone H3 gene (H3F3A and HIST1H3B) mutations encoding p.Lys27Met are frequent in DIPGs, which arise in the brainstem almost exclusively in children, and in pediatric HGGs in midline structures such as the thalamus and cerebellum, whereas histone H3 gene mutations encoding p.Gly34Arg or p.Gly34Val occur in pediatric HGGs of the cerebral cortex [3] [4] [5] 17 . In contrast, histone H3 gene mutations are extremely rare in adult HGGs 3 . HGGs arising in infants younger than 3 years of age have a better prognosis and a lower frequency of TP53 mutations, suggesting that there may be age-dependent subgroups of HGG, even within the pediatric population 2 . Thus, the selective pressures driving gliomagenesis in children vary with age and anatomical site.
To more comprehensively understand the pathways driving childhood glioma, we analyzed the genomic landscape of HGGs from 118 pediatric cases (127 tumors, 108 matched to germline DNA) consisting of 57 DIPGs and 70 NBS HGGs by whole-genome (n = 42), wholeexome (n = 80) and transcriptome (n = 75) sequencing ( Supplementary  Tables 1-9 ). A total of 39,590 sequence mutations, including singlenucleotide variations (SNVs) and small insertions or deletions (indels), and 2,039 structural variations were found by whole-genome sequencing, and an additional 2,600 sequence mutations and 138 structural variations were found by exome sequencing and transcriptome sequencing, respectively. Overall, the cohort showed a median background mutation rate of 9 × 10 −7 mutations per base and a median of 22 structural The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma Among recurrent mutations in pediatric HGG, the most frequently mutated gene not previously identified in cancer was ACVR1 (also known as ALK2) encoding a bone morphogenetic protein (BMP) type I 64 48 52 variations per genome ( Supplementary Fig. 1 ). All SNVs and structural variations found by whole-genome sequencing were verified experimentally by independent sequencing methods (Online Methods). Figs. 2 and 3) . Clonal missense ACVR1 mutations were found exclusively in DIPGs (32%) and were significantly associated with younger age, longer survival time and the presence of HIST1H3B mutation encoding p.Lys27Met (P < 0.0000001) or with PIK3CA or PIK3R1 mutations (P < 0.005) ( Figs. 1 and 2, Supplementary Fig. 3 and Supplementary Tables 4 and 5). Four of these somatic ACVR1 mutations were the same as germline mutations previously identified in the autosomal dominant syndrome fibrodysplasia ossificans progressiva (FOP), in which aberrant cellular differentiation drives progressive heterotopic ossifications 18, 19 . All residues affected by mutation in DIPGs clustered around either the inhibitory glycine-serine-rich (GS) domain or the ATP-binding pocket of the kinase domain and would be expected to shift the kinase to an active conformation ( Fig. 2 and Supplementary Fig. 3c ) 20 . Indeed, mutations affecting these residues induced a weak gain of function 20, 21 . A previous study showed that the ACVR1 mutation encoding p.Arg206His caused a ventralized phenotype in zebrafish embryos, an indicator of BMP pathway activation 22 . We tested all of the ACVR1 mutations found in DIPG using this assay. Zebrafish embryos injected with wild-type human ACVR1 mRNA displayed a mild dorsalized phenotype consistent with BMP pathway inhibition, whereas injection with mRNA for all six ACVR1 mutants resulted in varying degrees of ventralization, with partial to complete loss of head and dorsal structures (Fig. 2b,c and Supplementary Fig. 3d,e) . A moderate dose of LDN-193189, a highly selective antagonist of the BMP pathway 22, 23 , partially reversed the ventralization effects induced by ACVR1 mutants, as demonstrated by the rescue of dorsal head structures for the Arg258Gly, Gly328Glu, Gly328Trp and Arg206His mutants and the reduced severity of ventralization for the Gly356Asp and Gly328Val mutants ( Fig. 2c) Chromatin remodelers Figure 4 Pediatric HGG alterations in histone modifiers or chromatin regulators. Alterations identified in NBS-HGG or DIPG are shown. Genetic alterations were identified in proteins that attach (writers; above) or remove (erasers; below) post-translational modifications of lysine residues (Lys4, Lys9, Lys18, Lys27, Lys36) in the tail of histone H3, as well as proteins involved in modifications of other histones or chromatin remodelers. Notably, there were no alterations in writers or erasers of Lys27, which is directly mutated at high frequency in DIPG and, to a lesser degree, in NBS-HGG. Ub, ubiquitination; ac, acetylation; ph, phosphorylation; H2, histone H2; H4, histone H4. 
npg l e t t e r s a downstream indication of active BMP signaling, with varying magnitude ( Fig. 2d) . LDN-193189 also effectively blocked signaling to phosphorylated SMAD1/5 downstream of mutant ACVR1 in primary astrocytes ( Supplementary Fig. 3f ).
Recurrent and clonal activating mutation of ACVR1 in 32% of DIPGs provides strong evidence that ACVR1 is an oncogenic driver in this disease. However, germline ACVR1 mutation in the genetic syndrome FOP is not associated with cancer predisposition, indicating that ACVR1 mutation likely provides a selective advantage in the presence of other critical mutations rather than driving tumor initiation. Consistent with this hypothesis, all six of the DIPGassociated ACVR1 mutants failed to render Tp53-null mouse astrocytes tumorigenic when implanted into the brain (data not shown). BMP signaling is associated with contrasting effects dependent on context, driving astrocytic differentiation or the proliferation of early hindbrain progenitors 24 . In tumors, BMP signaling induced the differentiation of medulloblastoma 25 but drove either a differentiation or proliferation response in glioblastoma stem cells, related in part to the epigenetic state of the cell 26, 27 . These context-dependent consequences likely drive the exclusive association between ACVR1 mutation and DIPG.
Principal-component analysis using the 1,000 most variable probe sets showed that HGG samples clustered by tumor location with no segregation of DIPGs by ACVR1 mutation status ( Supplementary  Fig. 3g ). Genes involved in the regulation of immune system processes showed significantly different expression in DIPGs with and without ACVR1 mutation (Fisher's exact test, P = 0.0002, false discovery rate (FDR) = 0.26%) ( Supplementary Table 10 ).
Structural variants generating fusion genes were common and were identified in 47% of pediatric HGGs, in equal proportions of DIPGs and NBS-HGGs, from transcriptome and whole-genome sequencing data. Gene fusions involving the kinase domain of each of the three neurotrophin receptor (NTRK) genes and five different N-terminal fusion partners were identified in 4% of DIPGs and 10% of NBS-HGGs. Notably, 40% (4/10) of NBS-HGGs in children younger than 3 years old contained an NTRK fusion gene ( Figs. 1 and 3 , and Supplementary Tables 7 and 8). The NTRK receptors transduce a wide range of developmental signals in the nervous system, including the induction of neurite outgrowth, differentiation and neuronal survival or death 28, 29 . NTRK fusion genes have recently been identified at low frequency in low-grade pediatric astrocytomas as well as in adult glioblastomas [30] [31] [32] . Two of the five NTRK fusions found in our cohort, TPM3-NTRK1 and ETV6-NTRK3, were previously identified in other cancer types and shown to be oncogenic [33] [34] [35] [36] [37] .
To test the ability of NTRK fusion genes to drive glioma formation, we implanted Tp53-null primary mouse astrocytes transduced with retrovirus expressing Flag-tagged human TPM3-NTRK1 or BTBD1-NTRK3 into mouse brain. Both NTRK fusions induced high-grade astrocytomas with very short latency and complete penetrance ( Fig. 3b and Supplementary Fig. 4 ). The resulting tumors showed elevated levels of phosphorylated AKT and p42/44 mitogen-activated protein kinase (MAPK), downstream indicators of phosphoinositide 3-kinase (PI3K) and MAPK pathway activation.
Although NTRK-activating fusions were specifically found at high frequency in tumors from infants, activation of receptor tyrosine kinase (RTK)-RAS-PI3K signaling through other mutations was frequent across the entire cohort, occurring in 69% of DIPGs and 67% of NBS-HGGs ( Fig. 1, Online Methods and Supplementary Fig. 5) .
In contrast to previous reports detecting EGFRvIII expression in pediatric HGG 38, 39 , we only detected EGFRvIII expression in 1 of the 85 tumors analyzed by whole-genome sequencing or RNA sequencing (RNA-seq).
In addition to recurrent histone H3 gene, ATRX and SETD2 mutations reported previously [3] [4] [5] 17, 40 , we also detected frequent mutations of other histone writers and erasers and of chromatin-remodeling genes ( Fig. 4 and Supplementary Fig. 5 ). Interestingly, mutations affecting histone H3 writers were significantly more frequent in NBS-HGGs (P = 0.007), whereas frequencies of mutations affecting histone erasers were not significantly different in DIPGs and NBS-HGGs (P = 0.3). Although only ATRX mutations were highly recurrent, collectively, this group of genes involved in epigenetic regulation was targeted by mutation in 22% of DIPGs and 48% of NBS-HGGs, excluding histone H3 gene mutations ( Fig. 4 and Supplementary Fig. 5 ). These mutations were often concurrent with missense mutations in histone H3 genes. Indeed, including histone H3 gene mutations, 91% of DIPGs, 70% of midline NBS-HGGs and 48% of hemispheric NBS-HGGs contained mutations in histone genes and/or this subgroup of epigenetic regulators. p.Lys27Met histone H3.3 or H3.1 alteration results in a dominant loss of trimethylation at lysine 27 of histone H3 (H3K27me3) in the entire cellular pool of histone H3 proteins [41] [42] [43] [44] . Mutations that modulate H3K27me3 levels by targeting components of the Polycomb-repressive complex 2 (PRC2) that methylates H3K27 or the H3K27 demethylases KDM6A and KDM6B are found in other tumor types [45] [46] [47] [48] [49] [50] . However, there were no such mutations across the entire HGG cohort, including in DIPGs with wild-type histone H3 genes, supporting the unique selective advantage of p.Lys27Met alteration in pediatric HGG (Fig. 4) . Mutations in transcriptional regulators that affect the epigenetic landscape were also found, including focal amplifications of MYC and MYCN, which encode transcription factors that act to amplify the levels of expressed genes across the genome 51, 52 , and truncating mutations in the transcriptional corepressor genes BCOR and BCORL1 (Fig. 1) .
There was an enormous range in the complexity of the somatic mutations driving pediatric HGG (Supplementary Figs. 6 and 7) . The ten NBS-HGGs in children under 3 years old showed significantly lower mutation rates than the rest of the cohort (P < 0.0001), suggesting that only a small number of driver mutations is required in tumors from this age group ( Fig. 5 and Supplementary Fig. 7) . ETV6-NTRK3 fusion was identified as one of only two non-silent alterations in SJHGG082, a Figure 5 Circos plots showing the range of structural alterations in pediatric HGG. Circos plots display the genome by chromosome in a circular plot and depict structural genetic variants, including DNA CNAs, intra-and interchromosomal translocations, and non-sequence mutations. Orange, loss of heterozygosity (LOH); red, amplification; blue, deletion. Sequence mutations in RefSeq genes: brown, missense SNV; red, indel; blue, splice-site SNV. Genes at structural variation breakpoints: pink, gene involved in in-frame fusions; blue, others. Subject SJHGG003 carried a germline PMS2 mutation and developed two independent tumors, first a hemispheric malignant glioneuronal tumor (SJHGG003_D) and, 2 years later, a DIPG (SJHGG003_A). The SNVs and indels for these two tumors were too numerous to include. The hypermutator tumor with more than 800,000 somatic mutations had an extremely stable genome (SJHGG003_D), whereas the second tumor with approximately 100-fold fewer SNVs carried typical genomic copy number and structural abnormalities seen in other HGGs (SJHGG003_A), thus demonstrating the broad range and complexity of mutations associated with germline PMS2 mutation. SJHGG016_D is an infant NBS-HGG with a TPM3-NTRK1 fusion and a very stable genome. SJHGG027_D is an NBS-HGG from a case with A-T, showing a relatively stable genome. This tumor sample was collected before radiotherapy. SJHGG004_D is a DIPG with chromothripsis driving BTBD1-NTRK3 fusion, shown in more detail in supplementary Figure 8a . SJHGG044_D is an NBS-HGG showing dramatic chromothripsis. For the examples of chromothripsis, the names of the genes disrupted by structural variants were too numerous to display. l e t t e r s glioblastoma from a 1-month-old subject. Notably, NTRK fusion genes, including two of the fusions found here, have been identified in multiple tumor types, including those from very young children such as congenital fibrosarcoma, as well as in papillary thyroid cancer, an adult disease 30, [33] [34] [35] [36] . The high frequency of NTRK fusion genes in NBS-HGGs from children younger than 3 years of age, the paucity of additional mutations in these tumors and the rapid tumor onset in our experimental glioma model strongly suggest that these fusion genes are potent oncogenic drivers in early postnatal brain tumor development.
Four tumors, 3 with matched normal DNA, were scored as hypermutators, with an extremely high background mutation rate, including more than 800,000 somatic mutations in SJHGG111 in which biallelic germline PMS2 mutations were identified ( Supplementary  Fig. 7) . Subject SJHGG003 carried a heterozygous germline PMS2 mutation and developed a grade IV hemispheric malignant glioneuronal tumor (MGNT) and a separate DIPG. Although both tumors independently acquired different somatic inactivating mutations in the remaining PMS2 allele, the basal mutation rate in the first tumor arising in this case, the MGNT (SJHGG003_D), was nearly 100-fold higher than in the DIPG that arose 2 years later (SJHGG003_A), demonstrating the potential range in the tumor mutation burden associated with inherited mutation in DNA mismatch repair genes ( Fig. 5 and Supplementary Fig. 7) . Hypermutator tumors were excluded from the evaluation of mutation frequency. Seven cases carried germline mutations in known cancer predisposition genes, including TP53, PMS2, MSH6 and NF1 ( Supplementary Table 11 ).
Thirteen tumors (31%) analyzed by whole-genome sequencing had chromothripsis 53 , identified by complex rearrangements with multiple interconnecting breakpoints corresponding to genomic segments with oscillating copy number states ( Fig. 5, Supplementary  Figs. 6,8 and 9, Supplementary Table 12 and Supplementary Note). In our cohort, chromothripsis resulted in oncogenic rearrangement, including BTBD1-NTRK3 fusion and rearrangement or amplification of PDGFRA and EGFR (Supplementary Fig. 8) . Nearly half of all samples showing chromothripsis were collected before adjuvant therapy, indicating that the mechanism underlying their occurrence was, at least in some cases, independent of DNA-damaging therapeutics. SJHGG027_D, an NBS-HGG arising in a child with ataxia telangiectasia (A-T), had a relatively stable genome, despite a compromised DNA damage checkpoint due to the absence of functional ATM ( Fig. 5 and Supplementary Fig. 7) . Multiple subclones were identified in almost all HGG tumors. A founder clone or a descendant of a founder clone in the diagnosis tumor could seed the development of relapsed or autopsy tumor ( Supplementary Fig. 10 and Supplementary Note).
We identified TERT promoter mutations in only 2% of DIPGs and 3% of NBS-HGGs, in strong contrast to the frequency of 86% identified in adult primary glioblastomas 54 .
The genomic landscape of pediatric HGGs also includes frequent mutations in common cancer pathways, consistent with previous reports 3, [7] [8] [9] 11, 12, 15, 16 . TP53 mutations occurred in 42% of pediatric HGGs and were mutually exclusive with truncating mutations in the TP53-induced phosphatase PPM1D, previously shown to impair the TP53-dependent G1 cell cycle checkpoint (Fig. 1) 55 . The G1 checkpoint regulators CCND1, CCND2, CCND3, CDK4 and CDK6 were predominantly amplified in DIPGs, whereas CDKN2A homozygous deletion was restricted to NBS-HGGs (Fig. 1) . Taken together, mutations affecting cell cycle regulation, including the TP53 and RB pathways, were found in 59% of pediatric HGG ( Fig. 1 and Supplementary Fig. 5 ).
This global view of the genetic landscape of pediatric HGG defines critical pathways driving a devastating spectrum of childhood brain tumors and identifies high-frequency mutations in potential therapeutic targets-ACVR1 in DIPGs and NTRK fusions in NBS-HGGs in infants.
URLs. Pediatric Cancer Genome Project (PCGP) Explorer, http:// pcgpexplore.org/; DAVID Bioinformatics Resource, http://david.abcc. ncifcrf.gov/.
MeTHoDS
Methods and any associated references are available in the online version of the paper.
Accession codes. All whole-genome sequencing, whole-exome sequencing and transcriptome data have been deposited at the European Genome-phenome Archive (EGA), which is hosted by the European Bioinformatics Institute (EBI), under accession EGAS00001000192. Supplementary Table 1 . There was a significant association between sex and tumor subtype, with 63% female DIPG cases and 63% male NBS-HGG cases (P = 0.004).
The study cohort comprised 127 tumors (57 DIPGs and 70 NBS-HGGs; 54 DIPGs and 54 NBS-HGGs with matching germline samples) from 118 individuals in 2 cohorts: a cohort for whole-genome sequencing (n = 42, 20 DIPGs and 22 NBS-HGGs) and a cohort for evaluating the frequency of abnormalities using whole-exome sequencing (n = 80, 36 DIPGs and 44 NBS-HGGs). Six tumors and their matched germline samples, including two hypermutator tumors (SJHGG003_D and SJHGG111_D) and four non-hypermutator tumors (SJHGG003_A, SJHGG008_A, SJHGG019_E and SJHGG022_D), were sequenced by both whole-genome and whole-exome sequencing. Among these tumors, 75 (31 DIPGs and 44 NBS-HGGs) were characterized by RNA-seq. In addition, 12 tumors (3 DIPGs and 9 NBS-HGGs) were characterized by RNA-seq only for structural variant discovery.
Tumor tissue was available from diagnosis and relapse in five cases (SJHGG019_E/S, SJHGG024_D/R, SJHGG033_D/R, SJHGG112_D/R and SJHGG115_D/R) and from diagnosis and autopsy in three cases (SJHGG001_ D/A, SJHGG002_D/A and SJHGG093_D/A). One case developed two independent tumors, a hemispheric malignant glioneuronal tumor (SJHGG003_D) and a subsequent, independent DIPG (SJHGG003_A).
Histopathology was centrally reviewed by D.W.E., an experienced neuropathologist, and magnetic resonance imaging (MRI) of DIPG cases was reviewed by a pediatric neuro-oncologist (A.B.). DNA and RNA were extracted as previously described 56 .
Whole-genome, whole-exome and transcriptome sequencing and analysis.
Whole-genome sequencing, whole-exome sequencing and RNA-seq were performed as previously described 46, 57 . Paired-end sequencing was performed using the Illumina Genome Analyzer IIx or HiSeq platform with a 100-bp read length.
Whole-genome sequencing mapping, coverage and quality assessment, SNV and indel detection, tier annotation for sequence mutations, prediction of the deleterious effects of missense mutations and identification of LOH have been described previously 46, 57 . The reference human genome assembly GRCh37-lite was used for the mapping of all samples. Mapping statistics and coverage for each tumor on different sequencing platforms are summarized in Supplementary Table 2 .
SNVs were classified into the following four tiers, as previously described 46, 57 : (i) tier 1: coding synonymous, nonsynonymous, splice-site and noncoding RNA variants; (ii) tier 2: conserved variants (cutoff: conservation score ≥ 500, on the basis of either the phastConsElements28way table or the phastConsElements17way table from the UCSC Genome Browser, and variants in regulatory regions annotated by UCSC annotation (regulatory annotations included are targetScanS, ORegAnno, tfbsConsSites, vistaEnhancers, eponine, firstEF, L1 TAF1 Valid, Poly(A), switchDbTss, encodeUViennaRnaz, laminB1 and cpgIslandExt)); (iii) tier 3: variants in non-repeat-masked regions; and (iv) tier 4: the remaining SNVs.
All tier 1, tier 2 and tier 3 sequence mutations (including SNVs, indels and structural variations) discovered in non-hypermutator whole-genome sequencing samples were validated by a custom capture platform. The overall validation rate was 93%, with a median validation rate of 95% per sample. All tier 1 SNVs in the whole-exome sequencing cohort were also validated by custom capture. For all gene-coding indels found in whole-exome sequencing samples, we performed validation with the MiSeq platform, and the validation rate was 92% (167/182). Four non-hypermutator whole-genome sequencing samples (SJHGG003_A, SJHGG008_A, SJHGG019_E and SJHGG022_D) were subjected to exome sequencing, and the overlapping SNVs and indels were thus regarded as validated. Validated and high-quality variations for mutations in tiers 1-3 in non-hypermutator tumors are summarized in Supplementary  Tables 3-5 .
For two hypermutator whole-genome sequencing samples (SJHGG003_D and SJHGG111_D), exome sequencing served as validation. SNVs found in both whole-genome and whole-exome sequencing were regarded as having been validated. Validated and high-quality variations for tier 1 mutations in hypermutator tumors have been deposited at the PCGP Explorer website.
CNVs were identified by evaluating the difference in read depth between each tumor and its matching normal sample using a novel algorithm, CONSERTING (Copy Number Segmentation by Regression Tree in Next-Gen Sequencing; X.C., J. Wang, K. Roberts, M.P., S. Patel et al., unpublished data). The results are reported in Supplementary Table 6 .
Structural variations in whole-genome sequencing data were analyzed using CREST and were annotated as previously described 46, 58 . Custom capture was used to validate somatic structural variations found in whole-genome sequencing samples. The results are reported in Supplementary Table 7 .
Paired-end reads from RNA-seq were aligned to the following four database files using Burrows-Wheeler Aligner (BWA 0.5.5) 59 : (i) the human GRCh37lite reference sequence, (ii) RefSeq, (iii) a sequence file representing all possible combinations of non-sequential pairs in RefSeq exons and (iv) the AceView database flat file downloaded from UCSC representing transcripts constructed from human ESTs. The mapping results from databases (ii)-(iv) were aligned to human reference genome coordinates. The final BAM file was constructed by selecting the best alignment in the four databases. Structural variation detection was carried out with CICERO, a novel algorithm that uses de novo assembly to identify structural variation in RNA-seq data (Y.L., B. Tang, M.R., J.E., K.B. et al., unpublished data). The structural variants detected in RNAseq data were validated with MiSeq sequencing. Primer pairs were designed (with Primer3) to bracket the genomic regions containing putative structural variations. The structural variations found by RNA-seq are reported in Supplementary Table 8 .
Microarray copy number and expression analysis. Affymetrix SNP6.0 arrays were analyzed as described 8 . Candidate targets of focal amplification or deletion were identified from minimum common regions with copy number greater than 5 or less than 0.8. For DIPG samples, we also identified candidate targets of focal gain or loss as described 8 . Briefly, we derived minimum common regions for recurrent focal gain (copy number >2.3) or recurrent focal deletion (copy number <1.7) found in at least two tumors or that were classified as a single focal gain or deletion. Regions associated with known CNVs were removed. All remaining regions with fewer than 60 genes were manually inspected for cancer-and/or glioma-related genes, and candidate targets of focal gain or deletion were selected. Focal amplifications of MYC, MYCN, PDGFRA, MET, CDK4, CDK6, CCND1, CCND2 and CCND3, as well as focal deletions of CDKN2A and CDKN2B, from SNP data were included in Figure 1 because many samples sequenced only over the exome lacked these copy number data.
Affymetrix U133v2 expression array data were available for 71 HGGs, including 32 DIPG samples, 9 with ACVR1 mutation 8 . Principal-component analysis was performed using GeneMaths with the top 1,000 most variable probes selected on the basis of median absolute deviation (MAD) score. Differentially expressed genes in DIPGs with and without ACVR1 mutation were selected with linear models (limma/R; P value < 0.001), and enrichment of Gene Ontology (GO) terms among the selected genes was evaluated using the DAVID Bioinformatics Resource.
Frequency of mutations in pathways.
To summarize samples altered in RTK-RAS-PI3K pathways, we identified the relevant genes in the Kyoto Encyclopedia of Genes and Genomes (KEGG), Ingenuity and the National Cancer Institute (NCI)-Nature Protein Interaction Database and limited analysis to the following genes that had at least one somatic mutation in our study cohort: (i) RTKs: PDGFRA, KIT, EGFR, MET, CSF1R, FGFR1, FGFR3, FLT1, IGF1R, INSR, NRTK1, NTRK2 and NTRK3; (ii) phosphatidylinositol (3,4,5)-triphosphate (PIP 3 ) regulation: PTEN, PIK3CA and PIK3R1; (iii) ligands: FGF3, FGF5, FIGF, PDGFA and VEGFC; and (iv) downstream effectors: PLCG2, PLEKHA2, YES1, SGK1, G6PC, GNB1, GNGT1, MLST8, PHLPP1, PKN2, PPP2R2D, PRKAA2, PRKCA, PRKCZ, RAC1, RPS6, RPTOR, SGK3, npg STK11, INPP5D, SOS1, AKT3, JAK1, KRAS, MAP2K1, TSC2, GAB2, PPM1L, NF1, BRAF, RASGRF2 and RASSFS. To summarize the samples altered in cell cycle regulation, we included the following genes : TP53, TP73, CCND1,  CCND2, CDK1, CDK6, CDKN1B, CDKN2A, CDKN2B, CDKN2C, RB1, CDK4,  CCND3, RBL1 and CDC27. For DNA repair genes, we included the following:  ATR, ATM, BRCA1, RBBP8, RAD51, BRCA2, ERCC2, ERCC3, ERCC8, LIG4,  RAD23A, XAB2, MSH6, LIG1, LIG3, LIG4, POLD1, POLE, RAD23A, RAD50,  RAD54B , RUVBL2, SETX, PMS2 and UVRAG. To summarize samples altered in histone modifications and chromatin regulators, we limited our analysis to the following genes: (i) histone writers: MLL, MLL2, MLL3, MLL4, PRDM9, SMYD3, SETD1A, SETD2, SETD3 and ASH1L; (ii) histone eraser: JMJD1C, KDM2A, KDM3A, KDM3B, KDM4B, KDM5B, KDM5C and SIRT7; (iii) chromatin remodelers: ATRX, SMARCA4, BRWD1, CBX4, CHD2, CHD4, CHD6, CHD7, CHD8 and RAD54B; and (iv) other writers: UHRF1, NCOA1, STK4, UBR2 and UBR5. Therefore, our estimates of the numbers of mutations affecting these pathways are conservative.
TERT promoter mutation analysis. Owing to the high GC content of TERT promoter regions, there was poor coverage (~3× on average) in wholegenome sequencing at the two recurrently mutated sites (chr. 5: 1,295,228 and 1,295,250). Therefore, a portion of the TERT promoter (hg19 coordinates, chr. 5: 1,295,151-1,295,347) was amplified by PCR from tumors and matched normal samples and sequenced by Sanger sequencing using the primers listed in Supplementary Table 13 to check for two previously described TERT promoter SNVs. Sequence was analyzed using SNPDetector 60 , and manual review was performed using Consed 61 .
Statistical analysis. Association between ACVR1 mutation and age at diagnosis was analyzed by the Kruskal-Wallis test: H = 6.62, 1 degree of freedom, P = 0.010 (adjusted for ties). Association of ACVR1 mutation with the survival of individuals with DIPG was quantified by the log-rank test: χ 2 = 10.1, 1 degrees of freedom, P = 0.00149. On the basis of a two-variable Cox model for individuals with DIPG where age at diagnosis (as a continuous variable) and ACVR1 mutation status were included simultaneously, it appeared that age at diagnosis was not significantly associated with survival within this cohort (P = 0.55), but ACVR1 mutation status was (P = 0.0046). The co-occurrence of ACVR1 mutations with other mutations was quantified by Fisher's exact test: ACVR1 mutation co-occurrence with HIST1HB mutation encoding p.Lys27Met, P = 0.0000001 and ACVR1 mutation co-occurrence with PIK3CA and PIK3R1 mutations, P = 0.0049702.
The association between sex and tumor subtype (DIPG versus NBS-HGG) was quantified by Fisher's exact test. The association between tier 1 mutation rate and tumors in children less than 3 years of age was quantified by Kruskal-Wallis test (H = 13.42, 1 degree of freedom, P < 0.0001). The association between mutations in histone H3 writers and NBS-HGG was quantified by Pearson χ 2 (by Monte Carlo), P = 0.0007.
To identify samples with extremely high and low mutation rates, we used least median squares (LMS) as a method for the robust estimation of the center of the data and outlier detection 62 . Basically, LMS identifies the shortest interval that covers at least 50% of the data. This interval represents the densest 'bulk' of the data, and outliers are detected by comparing the data values to a normal distribution with the same interquartile range. Thus, the LMSidentified interval will not be influenced by outliers, and it can be used to detect such outliers.
Germline mutation analysis. We identified germline variants as previously described 63 . In this study, we implemented additional filters, where we (i) only kept genes listed in Cancer Gene Consensus or genes involved in DNA damage or repair and (ii) only kept nonsense or splice-site SNVs and indels, except a few missense mutations for TP53.
Zebrafish embryo injections. cDNA for wild-type or mutant human ACVR1 was cloned into pCS2, and mRNA was generated using the mMESSAGE mMACHINE kit (Life Technologies). Zebrafish embryos of the AB strain were microinjected with approximately 20 pg of wild-type or mutant ACVR1 mRNA at the one-cell stage. Embryos were inspected at 24 hours post-fertilization (h.p.f.) and scored as ventralized (classes V1-V5) or dorsalized (classes C1-C4) on the basis of published criteria 22, 23 . For chemical rescue, 2.5 µM LDN-193189 (Stemgent) was added to embryos at about 3 h.p.f.
Primary astrocyte transduction and in vivo tumorigenesis assays.
A sequence encoding a Flag tag was incorporated by PCR immediately before the termination codon of cDNA encoding the full ORF of human wild-type or mutant ACVR1, TPM3-NTRK1 and BTBD1-NTRK2, and the resulting fragments were cloned into the retroviral vectors MSCV-IRES-mCherry (MIC) 64 , which was modified by inserting an adaptor into a blunted EcoRI site to generate a Gateway cloning site, or MSCV-IRES-Puro (MIP) 65 . Sequences of all constructs were verified. Retrovirus was produced by transfecting HEK 293T cells with these viral constructs along with helper plasmids as previously described 66 . HEK 293T cells were from the American Tissue Type Collection (ATCC) and tested negative for mycoplasma.
Mouse experiments were approved by the St. Jude Children's Research Hospital Institutional Animal Care and Use Committee and are in compliance with national and institutional guidelines. Tp53-null primary mouse astrocytes were isolated from the cortex or brainstem of postnatal day 2 GFAP-cre; Trp53 loxP/loxP (Tp53 conditional knockout) mice 67, 68 and transduced with retroviruses as previously described 69 . Primary astrocyte cultures isolated from multiple mice were pooled for retroviral transductions to control for potential variation among primary cultures. For tumorigenesis studies, Tp53-null primary astrocytes at passage one were transduced with retroviruses generated from MIC vectors expressing human wild-type or mutant ACVR1, TPM3-NTRK1 or BTBD1-NTRK2 and implanted into female immunodeficient mice at 6-16 weeks of age as described 70 . When mice displayed brain tumor symptoms, tumors were dissected and fixed in 4% paraformaldehyde in PBS at 4 °C overnight. Tumors were then processed, embedded in paraffin and cut into 5-µm sections. Hematoxylin and eosin-stained sections from all collected tumors were evaluated by a clinical neuropathologist (D.W.E.). Immunohistochemistry was performed with microwave antigen retrieval, primary antibodies against phosphorylated AKT (Ser473) (Cell Signaling Technology, 9271; 1:50 dilution), phosphorylated p42/44 MAPK (Thr202/Tyr204) (Cell Signaling Technology, 4270; 1:400 dilution) or Flag (Sigma-Aldrich, F1804; 1:100 dilution), biotinylated secondary antibodies and horseradish peroxidase (HRP)-conjugated streptavidin (Elite ABC, Vector Labs), detected with NovaRED substrate (Vector Labs) and counterstained with hematoxylin (Vector Labs). For TPM3-NTRK1, BTBD1-NTRK2 and empty vector controls, seven mice were implanted for each construct. For empty vector control, wild-type ACVR1 or Gly328Glu, Arg258Gly or Arg206His ACVR1, seven mice were implanted for each construct, and, for Gly356Asp, six mice were implanted. A few of the immunodeficient mice were euthanized when they became ill without showing brain tumor symptoms (one expressing Gly328Glu ACVR1 at 97 d after implantation, one expressing Arg258Gly ACVR1 at 217 d after implantation, 2 expressing Gly356Asp at 139 and 190 d after implantation, and one expressing wild-type ACVR1 at 212 d after implantation). The remaining mice were euthanized between 219 and 222 d after implantation. Brains were formalin fixed and paraffin embedded, sectioned, stained with hematoxylin ad eosin, and evaluated for ACVR1-driven brain tumor growth both by analysis of hematoxylin and eosin-stained sections in the area surrounding the implantation site and by immunohistochemistry for the mCherry marker expressed as part of the bicistronic message with ACVR1. None of the mice showed brain tumor symptoms, and no histological evidence of ACRV1-driven tumor formation was detected in the entire cohort.
Protein blotting. For protein blotting, Tp53-null primary mouse astrocytes were isolated from neonatal brainstem and transduced at passage one with MIP retroviruses expressing wild-type or mutant ACVR1. After 48 h, cells were selected with 2.5 µg/ml puromycin for 48 h. For serum starvation, cells were washed twice with PBS and then incubated for 2 h in medium without serum or growth factors. For treatment with LDN-193189, cells were incubated in standard astrocyte growth medium 69 with vehicle (DMSO) or LDN-193189 (1 µM). Cells were lysed in RIPA buffer with protease and phosphatase inhibitors (Roche). Protein (20 µg) was resolved on 4-12% NuPAGE Bis-Tris gels, transferred to nitrocellulose membranes and detected with antibodies targeting phosphorylated SMAD1/5 (Cell Signaling Technology, 9516; 1:1,000 dilution), npg total SMAD1/5/8 (Santa Cruz Biotechnology, sc-6031; 1:500 dilution), phosphorylated p38MAPK (Invitrogen, 44-684G; 1:1,000 dilution), total p38MAPK (Cell Signaling Technology, 9212; 1:1,000 dilution), Flag (Sigma-Aldrich, F1804; 1:1,000 dilution) and tubulin (Santa Cruz Biotechnology, sc-23948; 1:1,000 dilution). After incubation with the appropriate HRP-conjugated secondary antibody, membranes were exposed to chemiluminescent substrate (SuperSignal West Dura, Thermo Scientific). Images were obtained with the Odyssey Imaging System (LI-COR Biosciences).
RT-PCR validation of NTRK fusions. Random-primed cDNA was generated by reverse transcription from tumor RNA and used for PCR to identify the fusion gene of interest. PCR products were analyzed by Sanger sequencing. Primers are listed in Supplementary Table 13 .
Statistical evaluation of chromothripsis in HGG tumors analyzed by whole-genome sequencing. Chromothripsis was described as localized chromosome shattering and repair occurring in a single event. The initial criterion was oscillation between 2 main CNV states 53 and was found in 15 HGG tumors in this study. Most recently, Korbel and Campbell 71 proposed four potential criteria for assessing chromothripsis: (i) clustering of breakpoints; (ii) randomness of DNA fragment joints; (iii) randomness of DNA fragment order; and (iv) ability to walk the derivative chromosome. Because randomness of DNA fragment order (criterion (iii)) was not entirely valid, even in Korbel and Campbell's own analysis, we decided not to evaluate this feature. For the 13 tumors in Supplementary Table 12 , we performed Bartlett's goodness-of-fit test for exponential distribution to assess whether the distribution of structural variation breakpoints in each tumor departed from the null hypothesis of random distribution. A significant departure from random distribution supports clustering of structural variation breakpoints. To evaluate whether there was any bias in the DNA fragment joints categorized by structural variation type (i.e., deletion, tandem duplication, head-to-head rearrangement or tailto-tail rearrangement), we applied the goodness-of-fit test separately for inter-and intrachromosomal events with a minimum of five structural variations. A significant P value suggests biased fragment joints, which would not support chromothripsis. When both inter-and intrachromosomal data were available, we reported the lower P value to represent a more conservative assessment of the random distribution for DNA fragment joints.
Details of tumor purity and tumor heterogeneity estimations and of tumor evolution analysis are included in the Supplementary Note.
